Herpes – Genital (HSV) / Adolescents and Adults

First Clinical Episode*
Recommended Regimen

Acyclovir† 400 mg orally 3 times/day for 7–10 days 

OR 

Famciclovir 250 mg orally 3 times/day for 7–10 days  

OR 

Valacyclovir 1 g orally 2 times/day for 7–10 days  

* Treatment can be extended if healing is incomplete after 10 days of  therapy.  

† Acyclovir 200 mg orally 5 times/day is also effective but is not  recommended because of the frequency of dosing. 

Alternative Regimen

None

Episodic Therapy for Recurrent HSV-2 Genital Herpes*
Recommended Regimen

Acyclovir 800 mg orally 2 times/day for 5 days 

OR 

Acyclovir 800 mg orally 3 times/day for 2 days 

OR 

Famciclovir 1 g orally 2 times/day for 1 day 

OR 

Famciclovir 500 mg orally once, followed by 250 mg 2 times/day for 2 days 

OR 

Famciclovir 125 mg orally 2 times/day for 5 days 

OR 

Valacyclovir 500 mg orally 2 times/day for 3 days 

OR 

Valacyclovir 1 g orally once daily for 5 days 

*Acyclovir 400 mg orally 3 times/day for 5 days is also effective but is not recommended because of frequency of dosing. 

Alternative Regimen

None

Suppressive Therapy of Recurrent HSV-2 Genital Herpes
Recommended Regimen

Acyclovir 400 mg orally 2 times/day 

 OR 

Valacyclovir 500 mg orally once a day* 

 OR 

Valacyclovir 1 g orally once a day 

 OR 

Famciclovir 250 mg orally 2 times/day 

* Valacyclovir 500 mg once a day might be less effective than other valacyclovir or acyclovir dosing regimens for persons who have frequent recurrences (i.e., ≥10 episodes/year) 

Alternative Regimen

None

Suppressive Therapy of Recurrent HSV-1 Genital Herpes

Recurrences are less frequent after the first episode of HSV-1 genital herpes, compared with genital HSV-2 genital herpes, and genital shedding rapidly decreases during the first year of infection. No data are available regarding the efficacy of suppressive therapy for preventing transmission among persons with HSV-1 genital herpes infection. Because of the decreased risk for recurrences and shedding, suppressive therapy for HSV-1 genital herpes should be reserved for those with frequent recurrences through shared clinical decision making between the patient and the provider.

Page last reviewed: July 16, 2021
Content source: